Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Plots Five-Year Pharma Growth Plan Around Mega-Brands And Launches

Executive Summary

Management outlined how the company plans to achieve above-market compound-annual growth from 2016 to 2021 during an R&D Day near its New Jersey headquarters.

Advertisement

Related Content

Janssen Enriches Crohn's Portfolio In Deal For Protagonist's Oral IL-23 Inhibitor
J&J Forges Ahead In Immunology Despite Competitive Dynamics
Invokana Adds Warnings On Amputation Risk, But Will It Give Jardiance An Edge?
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC098763

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel